> Caution is advised when BISPHOSPHONATES are administered with aminoglycosides , calcitonin or LOOP DIURETICS , since these  agents may have an additive effect, resulting in a lower serum CALCIUM level for longer periods than required (see section 4.4) .
> In multiple myeloma patients, the risk of renal dysfunction may be increased when ZOLEDRONIC ACID ACTAVIS is used in combination with THALIDOMIDE. 
> Caution is advised when ZOLEDRONIC ACID ACTAVIS is administered with ant i-angiogenic medicinal products , as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products .
